The Clinicopathologic Importance of Serum Lactic Dehydrogenase in Patients with Gastric Cancer

Table 2

The SLDH levels in gastric cancer patients.

Variable	(%)	SLDH (U/L, mean ± SD)
Age (y)			0.675^a
<60	223 (61.1)	163.8 ± 36.5
≥60	142 (38.9)	165.0 ± 38.2
Gender			0.334^a
Male	240 (94.2)	162.9 ± 37.2
Female	125 (92.8)	166.9 ± 37.1
Tumor size (cm)			0.214^a
≤4	196 (53.7)	154.6 ± 38.2
>4	169 (46.3)	159.3 ± 31.7
Borrmann type			0.027^b
I	11 (3.0)	184.5 ± 42.0
II	70 (19.2)	155.0 ± 32.5
III	240 (65.8)	164.8 ± 37.3
IV	44 (12.1)	171.0 ± 39.5
Histological type			0.242^a
Well diff. ade.	7 (1.9)	154.2 ± 45.9
Moderately diff. ade.	83 (22.7)	162.2 ± 33.1
Poorly diff. ade.	268 (73.4)	165.6 ± 38.0
Undifferentiated ade.	4 (1.1)	171.0 ± 43.2
Squamous cell ca.	3 (0.8)	120.0 ± 6.55
pT stage			0.004^a
T1 + T2	61 (16.7)	151.9 ± 32.4
T3 + T4	304 (83.3)	166.8 ± 37.6
Lymph node metastasis			0.027^a
No	84 (23.0)	156.4 ± 31.9
Yes	281 (43.0)	166.6 ± 36.3
Metastasis			<0.001^a
No	292 (80.0)	159.6 ± 34.3
Yes	73 (20.0)	183.1 ± 42.1
pTNM stage			0.006^a
I + II	99 (16.7)	155.5 ± 34.1
III + IV	266 (83.3)	167.6 ± 37.7
Recurrence			0.002^a
No	218 (59.7)	159.1 ± 34.0
Yes	147 (40.3)	172.0 ± 40.3
Survival			0.001^a
Alive	216 (59.2)	158.6 ± 33.5
Dead	149 (40.8)	172.5 ± 40.5

SLDH: serum lactate dehydrogenase; ade.: adenocarcinoma; ca.: carcinoma; SD: standard deviation.
^aIndependent -test; ^bone-way ANOVA test; p: pathological; .